Mitochondrial Health and Aging

Evidence Review

Foundational Preclinical Work: Ryu et al. 2016

The study that put urolithin A on the scientific map was published in Nature Medicine (PMID 27400265). Ryu and colleagues at the Auwerx lab (EPFL, Switzerland) screened natural compounds for their ability to stimulate mitophagy, and identified urolithin A as the first food-derived compound capable of activating the PINK1/Parkin pathway in vivo.

In C. elegans, urolithin A extended median lifespan by approximately 45% and preserved physical activity (pharyngeal pumping, mobility) during aging. Critically, these effects were abolished in dct-1 mutants lacking the worm homolog of BNIP3L, a key mitophagy receptor — confirming that the benefits were mitophagy-dependent rather than simply antioxidant effects.

In rodents, elderly mice receiving urolithin A showed improved treadmill endurance and grip strength compared to age-matched controls. Skeletal muscle analysis showed reduced accumulation of dysfunctional mitochondria and upregulation of mitophagy pathway genes. The translational relevance was supported by demonstrating that urolithin A activates the same PINK1/Parkin pathway in human primary myotubes (muscle cells derived from human biopsies). This preclinical dataset was unusually thorough, providing a mechanistic basis that directly informed the subsequent human trials.

First Human Trial: Andreux et al. 2019

The transition to humans was published in Nature Metabolism (PMID 32694802) by Andreux, Blanco-Bose, Ryu, and colleagues — a collaboration between EPFL and the company Amazentis. This was a randomized, double-blind, placebo-controlled trial in 60 healthy but sedentary adults aged 65 and older.

The study had two phases: a single-dose pharmacokinetic evaluation (doses of 250, 500, 1,000, or 2,000 mg) and a 4-week multiple-dose intervention at 500 mg and 1,000 mg. The main findings:

• Urolithin A was safely absorbed at all doses with no adverse events
• At 4 weeks, plasma acylcarnitine profiles shifted significantly in the 500 mg and 1,000 mg groups — indicative of improved mitochondrial fatty acid oxidation efficiency
• Skeletal muscle biopsies showed upregulation of genes involved in oxidative phosphorylation, mitochondrial biogenesis, and mitophagy
• The molecular changes were more pronounced at 1,000 mg than 500 mg

This study was the proof-of-concept that urolithin A reaches relevant tissues in humans and engages the intended pathway. It did not have the statistical power to detect functional improvements (that was by design), but the biomarker data supported proceeding to larger trials.

Older Adult RCT: Liu et al. 2022

Liu, D'Amico, Shankland, and colleagues (PMID 35050355) conducted a 4-month double-blind RCT in 66 adults aged 65–90, randomized to 1,000 mg urolithin A or placebo daily, at medical centers in Seattle. The primary endpoints were 6-minute walk distance and maximal skeletal muscle ATP production (measured by phosphorus magnetic resonance spectroscopy, a demanding functional readout).

Neither primary endpoint reached statistical significance. The 6-minute walk distance improved by 8.7 meters in the urolithin A group versus 6.0 meters in placebo — a clinically modest difference that was not significant given the sample size. ATP production showed a trend toward improvement (5.5% greater in the UA group) but again was not significant.

Secondary endpoints told a different story. Hand grip endurance (number of contractions until fatigue at 80% maximal voluntary contraction) improved significantly: 44% more contractions in the UA group versus placebo (P = 0.03). Leg endurance similarly improved. Plasma citrate synthase activity, a mitochondrial mass marker, increased significantly in the UA group. The researchers note that the functional improvements in ATP production and walking capacity may require longer intervention periods or younger, less-limited populations to reach significance. The muscle endurance finding, combined with favorable biomarker changes, was considered sufficient to support continued clinical development.

Middle-Aged Adult RCT: Singh et al. 2022

This trial (PMID 35584623) enrolled 112 adults aged 40–64 — a population with less baseline functional impairment than the older-adult trial — and randomized them to placebo, 500 mg/day, or 1,000 mg/day of urolithin A (Mitopure) for 4 months. This design allowed dose-response analysis and functional detection in a pre-frailty population.

Key results for the 1,000 mg group versus placebo:

• Hand grip strength: +12.4% (P < 0.05)
• Maximal aerobic capacity (peak VO2): clinically meaningful improvement
• 6-minute walk test: favorable trend
• Plasma C-reactive protein: significantly reduced
• Plasma acylcarnitines: significantly reduced (mitochondrial efficiency improvement)
• Skeletal muscle protein expression: significant increases in LC3-II/I ratio (autophagy activation marker), p62 reduction (consistent with active mitophagy flux), and TFAM (mitochondrial transcription factor A, marker of mitochondrial biogenesis)

The 500 mg group showed intermediate effects, with some but not all endpoints reaching significance. The 1,000 mg dose was the more consistent performer. The muscle biopsy data directly linking molecular pathway activation to functional outcome is particularly valuable — it provides mechanistic confirmation that the muscle strength improvements are driven by the intended mitophagy and mitochondrial pathway, not confounding variables.

Metabolism and Microbiome Review: Zhao and Jiang 2022

This comprehensive review (PMID 35118817) synthesizes the research on urolithin metabolism, individual variability, and associated gut microbiota. Key points relevant to clinical interpretation:

Urolithin metabotyping (UM) classifies people into three groups: UM-A (produce urolithin A predominantly), UM-B (produce urolithin A and urolithin B/isourolithin A), and UM-0 (produce little or no urolithins). In population studies, UM-A individuals show better cardiometabolic biomarkers than UM-B or UM-0 individuals. The review identifies Akkermansia muciniphila, Gordonibacter pamelaeae, and Gordonibacter urolithinfaciens as key bacterial species in the conversion pathway.

Practically, this review underscores why supplementation with purified urolithin A bypasses the microbiome variability problem that limits dietary polyphenol research. The 30–50% of the population in the UM-0 or UM-B categories can achieve the same plasma levels through supplementation that UM-A individuals achieve from food. This is an unusual situation where a supplement provides genuinely different value for people whose gut microbiome cannot complete the conversion.

Overall Evidence Assessment

The urolithin A evidence base is unusually coherent for a nutritional supplement. The preclinical mechanism is well-characterized, the pathway (PINK1/Parkin mitophagy) is biologically validated and disease-relevant, and multiple human RCTs show consistent biomarker changes. Functional evidence is strongest in the middle-aged population (2022 Cell Reports Medicine trial), and more modest but still present in older adults. The compound's safety profile is clean across all completed trials.

The main limitations are the relatively modest sample sizes (66–112 participants per trial), trials conducted or funded by the company that makes Mitopure (introducing sponsorship bias risk), and the lack of long-term (>6 month) data. Independent replication is needed. That said, the mechanistic grounding and multi-trial consistency place urolithin A among the better-evidenced supplements for mitochondrial health and muscle aging — a category where most competitors lack any human trial data at all.